TAS3351, TAS3351, TAS3351 clinical trials

A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations

This study is testing a new medicine called TAS3351 for people with a type of advanced lung cancer. It's for patients whose cancer has a specific change (EGFR mutation) that has become resistant to previous treatments. Researchers want to see if the medicine is safe and how well it works.